COVID-19 Alert: Blue Water Capital Management, LLC is primarily working from home offices and using remote meetings, but can meet in-person as well.
If you have concerns about the markets, or would like to have us look over your investments, please feel free to contact us.

Specializing in retirement planning and personalized investment management.

Healthcare: BioTech & Genomics

Biotechnology is biology-based technology that harnesses cellular and biomolecular processes to develop technologies and products that help improve people’s lives.

Genomics is the study of a person's genome (all their DNA), and the interactions of their genes with each other and with the person's environment. It allows for medicine and therapies to be tailored to meet each patient's specific needs. Read about the innovation happening in genomics.

There are a wide range of funds focused on biotech and genomics. These can be used to increase your portfolio’s exposure to various biotechnologies and medical advancements.

Note: These are not recommendations, just investment ideas for further research.

Fund Ticker Expense Holdings Inception
ALPS Medical Breakthrough SBIO 0.50% 92 12/30/14
  Tracks the Poliwogg Medical Breakthroughs Index, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.
ARK Genomic Revolution ARKG 0.75% 39 10/30/14
  Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business.
Defiance NASDAQ Junior Biotechnology IBBJ 0.45% 177 8/3/20
  The underlying Nasdaq Junior Biotechnology Index tracks approximately 176 smaller-cap companies listed on NASDAQ from over 16 countries. Included companies are those involved in genomics, DNA technology, genetic engineering, and molecular biology, as well as pharmaceutical manufacturers of prescription or over-the counter drugs.
ETFMG Treatments Testing and Advancements GERM 0.68% 57 6/17/20
  Designed to give exposure to the biotech companies directly engaged in the testing and treatments of infectious diseases. Focused on advancements with targeted exposure to the forefront of R&D, vaccines, therapies and testing technologies.
First Trust NYSE Arca Biotech FBT 0.55% 31 6/19/06
  Based on an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
Franklin Genomic Advancements HELX 0.50% 56 2/25/20
  Provides access to companies benefitting from or facilitating the use of new research including DNA sequencing, gene editing and personalized medicine.
Global X Genomics & Biotechnology GNOM 0.50% 42 4/5/19
  Seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.
Invesco Dynamic Biotech & Genome PBE 0.58% 32 6/23/05
  Based on the Intellidex Index, which is comprised of securities of 30 US biotechnology and genome companies that are principally engaged in the research, development, manufacture, marketing and distribution of various biotechnological products, services and processes.
iShares Evolved US Innovative Healthcare IEIH 0.18% 259 3/21/18
  Tracks an index that offers US pharmaceutical and biotechnology exposure as defined by the iETF Evolved Sector classification scheme.
iShares Genomics Immunology & Healthcare IDNA 0.47% 54 6/11/19
  Seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.
iShares NASDAQ Biotechnology IBB 0.46% 212 2/5/01
  Seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ.
Loncar Cancer Immunotherapy CNCR 0.79% 31 10/13/15
  Tracks the Loncar Cancer Immunotherapy Index, an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs.
Pacer BioThreat Strategy VIRS 0.70% 46 6/24/20
  Seeks to track the LifeSci BioThreat Strategy Index to invest in U.S. listed companies whose products or services help to protect against, endure or recover from biological threats to human health.
SPDR S&P Biotech XBI 0.35% 134 1/31/06
  Provides exposure to one of the broadest portfolios among US biotech ETFs. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk.
VanEck Vectors Biotech BBH 0.35% 25 12/20/11
  Seeks to replicate the MVIS® US Listed Biotech 25 Index, which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.
Virtus LifeScience Biotech Clinical Trials BBC 0.79% 133 12/16/14
  Tracks the LifeSci Biotechnology Clinical Trials Index is designed to track the performance of U.S.-listed biotechnology stocks with a lead drug in the clinical trial stage of development, typically a Phase 1, Phase 2 or Phase 3 trial, but prior to receiving marketing approval.
Virtus LifeScience Biotech Products BBP 0.79% 46 12/16/14
  Offers a different approach to biotech investing by handpicking firms whose lead drugs are on its product stage or those firms that have attained FDA approval for their leading drug.